An Adult Mouse Model of Dilated Cardiomyopathy Caused by Inducible Cardiac-Specific <i>Bis</i> Deletion

BCL-2 interacting cell death suppressor (BIS) is a multifunctional protein that has been implicated in cancer and myopathy. Various mutations of the <i>BIS</i> gene have been identified as causative of cardiac dysfunction in some dilated cardiomyopathy (DCM) patients. This was recently v...

Full description

Bibliographic Details
Main Authors: Hye Hyeon Yun, Soon Young Jung, Bong Woo Park, Ji Seung Ko, Kyunghyun Yoo, Jiyoung Yeo, Hong Lim Kim, Hun Jun Park, Ho Joong Youn, Jeong Hwa Lee
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/22/3/1343
Description
Summary:BCL-2 interacting cell death suppressor (BIS) is a multifunctional protein that has been implicated in cancer and myopathy. Various mutations of the <i>BIS</i> gene have been identified as causative of cardiac dysfunction in some dilated cardiomyopathy (DCM) patients. This was recently verified in cardiac-specific knock-out (KO) mice. In this study, we developed tamoxifen-inducible cardiomyocyte-specific BIS-KO (<i>Bis</i>-iCKO) mice to assess the role of BIS in the adult heart using the Cre-loxP strategy. The disruption of the <i>Bis</i> gene led to impaired ventricular function and subsequent heart failure due to DCM, characterized by reduced left ventricular contractility and dilatation that were observed using serial echocardiography and histology. The development of DCM was confirmed by alterations in Z-disk integrity and increased expression of several mRNAs associated with heart failure and remodeling. Furthermore, aggregation of desmin was correlated with loss of small heat shock protein in the <i>Bis</i>-iCKO mice, indicating that BIS plays an essential role in the quality control of cardiac proteins, as has been suggested in constitutive cardiac-specific KO mice. Our cardiac-specific BIS-KO mice may be a useful model for developing therapeutic interventions for DCM, especially late-onset DCM, based on the distinct phenotypes and rapid progressions.
ISSN:1661-6596
1422-0067